Lundbeck’s billion-dollar epilepsy drug buy

Lundbeck is acquiring Longboard Pharmaceuticals for $2.5 billion to secure an epilepsy drug, Bexicaserin, targeting rare conditions like Dravet and Lennox-Gastaut syndromes. Bexicaserin has blockbuster potential with projected annual sales of $2 billion and a planned launch for the end of 2028. The deal aligns with Lundbeck’s focus on severe brain disorders, and despite initial stock drops, it promises substantial growth into the next decade. The acquisition is pending regulatory approval. Lundbeck is known for producing treatments for brain diseases, including its leading drugs Vyepti for migraines and Rexulti for schizophrenia. The latter accounted for a fourth of Lundbeck’s total turnover last year.